OBJECTIVES: Although significant improvement in myasthenic symptoms has been reported following the removal of thymolipomas, information on surgical outcomes among patients with thymolipomatous myasthenia gravis (MG) is limited.
INTRODUCTION
Thymolipoma is a rare and slow-growing mediastinal tumour comprised of mature adipose tissue and benign thymic tissue. Thymolipoma was first described by Hall [1] in 1949 and is estimated to account for 2-9% of all thymic neoplasms [2] . According to the reports in the literature, thymolipoma occurs more frequently in younger patients [3] , is asymptomatic and is characterized by very large anterior mediastinal masses on chest radiography [4] . Similar to thymoma and other anterior mediastinal tumours, thymolipoma has been reported to simultaneously occur alongside other autoimmune diseases, such as Grave's disease [5] , aplastic anaemia, hypogamma-globulinemia and myasthenia gravis (MG) [6, 7] .
Significant improvement in myasthenic symptoms has been reported after the removal of anterior mediastinal tumours [8] , including thymolipomas [6, [9] [10] [11] [12] . However, there are only a small number of documented cases and most reports have been focused on non-myasthenic thymolipoma [3, 4, 13] . Furthermore, there is limited information regarding surgical outcomes among patients with myasthenic thymolipomas in comparison with patients with thymomatous and non-thymomatous MG. Therefore, the aim of this study was to review surgical outcomes among myasthenic patients with thymolipomas at a single institution.
MATERIALS AND METHODS
The medical records of patients who underwent extended thymectomy for MG in Taipei Veterans General Hospital database from January 1995 to December 2010 were reviewed. The clinical demographic characteristics of the patients, including age, sex, preoperative myasthenic grading, preoperative anti-acetylcholine receptor antibody (AchRAb) level, histological type of tumour(s) and the surgical approach(es) used were retrieved for further analysis.
The study was approved by the Institutional Review Board of Taipei Veterans General Hospital (approval No. 2013-03-007AC). Individual informed consent was waived because patient management was performed according to our normal clinical practices, with no added experimental elements.
Diagnosis and outcome evaluation
The diagnosis of MG and disease severity (maximum severity before surgery) were evaluated by a specialized neurologist (K.P.K.) according to the modified Osserman's classification, which was used to assess most patients throughout their preoperative care and postoperative follow-up. Class I patients experienced ocular involvement only. Class IIa patients experienced mild generalized weakness. Class IIb patients experienced moderate generalized weakness, mild bulbar dysfunction or both. Class III patients experienced severe generalized weakness, respiratory failure or both.
Outcomes were classified as complete stable remission (CSR), improvement, non-improvement or worse. CSR was defined as patients who experienced no symptoms or signs and did not have the need for medication for at least 12 months during the followup period. Improvement was defined as patients experiencing increased activity with less medication or being asymptomatic on the same dosage as needed before operation. Non-improvement was defined as patients experiencing no substantial decrease in pretreatment clinical manifestations or experiencing a substantial reduction in the need for MG medications. Worse was defined as patients experiencing deterioration of clinical status with worse symptoms, requiring more medication or both of the aforementioned [14] .
Surgical indications and management protocols
Indications for surgical treatment included suspected coexistent thymoma, severe generalized MG, early generalized MG with a short duration of illness, isolated ocular type with abnormal thymic lesion or a poor response to medical control. The preoperative workup included a compete blood count, serum biochemistry, serum AchRAb, chest computed tomography (CT) scan, pulmonary function test and assessment of ejection fraction and wall motion for evaluation of cardiac function. The necessity of preoperative plasmapheresis was evaluated to minimize the required dose of steroid and Mesntion ( pyridostigmine bromide), and thus to reduce the likelihood of postoperative myasthenia crisis. Steroids (methylprednisolone sodium 1000 mg) were given before surgery, during surgery, after surgery and before oral medicine intake. After surgery, patients were sent to the postoperative recovery room for 6 h and then back to the ordinary ward if there was no obvious evidence of myasthenia crisis. The endotracheal tube was removed either in the operative theatre or in the postoperative room. In most cases, patients were transferred to the intensive care unit for further observation for 1 day. The myasthenia medicine was represcribed if the oral intake began. The pleural drainage tube was removed if the amount of pleural effusion was <200 ml/24 h.
Chest CT and histopathology
As shown in Fig. 1 , routine chest CT scans were obtained before thymectomy to evaluate the presence of an anterior mediastinal tumour mass. All images were reviewed by a specialized thoracic radiologist (M.H.W.). The histology of all resected tumour specimens was reviewed by two special histopathologists experienced in thoracic pathology (W.Y.L. and T.Y.C.). Thymolipoma was indicated by a well-circumscribed tumour comprising mature adipose tissue with interspersed islands of non-neoplastic thymic tissue [15] .
Surgical approaches
Most patients underwent trans-sternal extended thymectomy (TET). From 1998 onwards, right-sided video-assisted thoracoscopic extended thymectomy (RtVATET) was used for the treatment of some selected patients at our institution. The surgical details have been comprehensively described in previous reports [14, 16] .
Trans-sternal extended thymectomy. Our standard surgical approach for TET was carried out by median sternotomy. After entering the mediastinum, both pleura were opened. The thymus, along with the adjacent pericardial fat, was freed from the pericardium and mediastinal pleura. The cervical extension of each lobe was easily removed with the body of the gland by gentle traction.
Right-sided video-assisted thoracoscopic extended thymectomy. Three trocars were placed sequentially at the sixth intercostal space, third intercostal space mid-axillary line and the fifth intercostal space, anterior to the axillary line. After right lung collapse, the adipose tissue was dissected from the most inferior portion of the anterior mediastinum, just anterior to the phrenic nerve and above the diaphragm, using ultrasonic cutting (Harmonic, Ethicon Endo-Surgery, Somerville, NJ, USA). The dissection was then turned in the cephalic direction along the pericardium; the bilateral mediastinal pleura were divided just below the sternum. The bilateral thymic arteries, originating from the internal mammary arteries, and the draining thymic veins were identified and ligated with endoclips to the superior vena cava and left innominate vein level. The superior ligament of the thymus was then identified and both upper poles of the thymus gland were freed from the cervical area by sharp dissection.
Follow-up
Post-thymectomy outpatient department follow-up visits occurred every 3 months for the first 2 years, every 6 months from the third to fifth year, and annually thereafter. Follow-up assessments were performed by a neurological specialist (K.P.K.). The postoperative status of MG was assessed by K.P.K. 1, 3 and 6 months after surgery, and annually thereafter. Chest CT scans were performed annually to monitor potential recurrence.
For the analysis of outcomes, time zero was defined as the date of thymectomy, while the terminal event was defined as the time to CSR. Follow-up information was obtained by reviewing the hospital electronic database or via telephone. All patient follow-up was complete as of 30 April 2013, with the exception of 12 patients (4.5%) who were lost to follow-up. For these patients, the clinical outcome was taken as that determined at the last follow-up visit.
Statistical analysis
Continuous data are presented as mean ± standard deviation and were analysed using one-way analysis of variance or the KruskalWallis test, as warranted. Categorical data are presented as number ( percent) and were analysed using the χ 2 test with linear-by-linear association [17] . We chose to use the χ 2 test with linear-by-linear association (rather than Pearson's χ 2 test) because, based on one degree of freedom, this test is more conservative than Pearson's χ 2 test [17] . Kaplan-Meier plots of CSR were constructed. The log-rank test was performed to test the null hypothesis that there was no difference between groups in the probability of CSR at any time point. A P-value of <0.05 was considered to indicate statistical significance. All statistical analyses were carried out using the Statistical Package of the Social Sciences software programme (SPSS, version18.0, Chicago, IL, USA).
RESULTS
The algorithm for patient selection is shown in Fig. 2 . During the defined study period, 267 patients underwent thymectomy for MG. Among these patients, 104 were diagnosed with thymomatous MG and 151 were diagnosed with non-thymomatous MG (106 thymic hyperplasia, 38 normal thymic tissue and 7 thymic cysts). A total of 12 (4.4%) patients had thymolipoma. Table 1 summarizes the demographic and clinical characteristics of the patients by study grouping. Patients in the nonthymomatous group (36.1 years) were significantly younger than those in the thymolipomatous group (47.9 years, P < 0.001) and the thymomatous group (50.0 years, P = 0.022). There was a significant difference in sex distribution between the three groups (P = 0.016). Similar to the non-thymomatous group, there was a female predominance in the thymolipoma group relative to the thymomatous group. Patients in the thymolipoma group had a significantly greater duration of myasthenic symptoms before surgery (59.1 months) compared with the thymomatous group (P < 0.001) and the non-thymomatous group (P = 0.02). The mean preoperative serum level of AchRAb was significantly different among the groups (P = 0.015), being lowest in the non-thymomatous group, followed by the thymolipoma group, and then the thymomatous group. Regarding the weight of the removed specimen, significantly more thymic and adipose tissue was removed in the thymolipomatous group compared with the non-thymomatous group (P < 0.001). There were no preoperative between-group differences in myasthenic grading distribution. Table 2 summarizes further details regarding the preoperative characteristics of the 12 patients with MG and thymolipoma. Among these patients, there were 5 males and 7 females, with a mean age at the time of thymectomy of 47.9 years (range: 33-64 years). The distribution of preoperative MG classification was as follows: 3 patients in Class I, 2 patients in Class IIa and 6 patients in Class IIb. One patient experienced preoperative respiratory failure. The mean duration of MG symptoms before surgery was 59.1 months (range: 6-180 months). Of the 12 patients, 10 (83.3%) received preoperative steroid treatment to control myasthenic symptoms. Table 3 summarizes the procedures performed and the surgical outcomes for the 12 patients with myasthenic thymolipoma. Three patients (25%) were seronegative for MG. Preoperative chest CT scans revealed that 3 patients had thymus hyperplasia and that 2 patients had small or very small thymomas. Two patients had Graves' disease. For the surgical approach, aside from 2 patients who underwent RtVATET, the other 10 patients underwent TET. The average weight of resected thymus tissue among patients who underwent extended thymectomy was 127 g (range: 38-250 g). During a median follow-up of 114.5 months, 5 patients achieved CSR, 6 patients achieved improvement and 1 patient experienced non-improvement. The overall rate of improvement among these patients was 91.7%. Aside from 1 patient who experienced postoperative chylothorax and sternal wound infection, there were no other perioperative complications. Table 4 compares the surgical results for each group of patients with MG. During the follow-up, there were no instances of tumour recurrence in the thymolipomatous group, whereas 9 patients experienced tumour recurrence in the thymomatous group (P = 0.289). The rate of myasthenic CSR was lower in the thymomatous group compared with the thymolipomatous and non-thymomatous groups (P = 0.029). The duration of surgery was significantly longer 
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C.-S. Huang et al. / Interactive CardioVascular and Thoracic Surgeryin the thymomatous group compared with the non-thymomatous group (P < 0.001). The volume of blood loss was significantly greater in the thymomatous group compared with the nonthymomatous group (P = 0.026). There were no significant between-group differences in the duration of hospital or intensive care unit stay or in the occurrence of postoperative complications. Figure 3 illustrates the cumulative Kaplan-Meir estimates of CSR for each group. There were no between-group differences in the probability of a CSR event at any time point during the follow-up period as determined by log-rank test (P = 0.261).
DISCUSSION
Thymolipoma is a rare, benign tumour of the anterior mediastinum that accounts for 2-9% of all thymic neoplasms. The incidence of MG associated with thymolipomas is between 2.8 and 50% [9] . In the current study, 12 of 267 (4.4%) myasthenic patients who underwent extended thymectomy were diagnosed with thymolipoma.
It is difficult to diagnose myasthenic thymolipoma preoperatively according to clinical symptoms and signs, radiological examination findings and serum immunological studies. Fatigue and chest pain are the most common symptoms of large thymolipoma in non-myasthenia patients [10] . Aside from myasthenic symptoms, only two thymolipomatous patients with MG complained of chest pain in our cohort. These patients had tumour dimensions of 9 × 9 × 3 and 4 × 3 × 3 cm 3 , respectively. Preoperative chest CT scans revealed that only 2 of 12 patients had a suspected small thymoma or cystic lesion; all others presented with hyperplasia of thymic tissue or a negative finding. All but 3 (25%) patients with thymolipomatous MG had elevated serum AchRAb titres. Two of the seronegative patients achieved CSR after resection of the thymolipoma. This finding is similar to that reported by Rieker et al. [9] . Further studies included a serum muscle-specific kinase titre to rule out the definitive double-negative MG as being crucial to clarify its clinical implication for thymolipoma autoantibodies.
The duration of myasthenic symptoms before surgery was longest in the myasthenic thymolipoma group compared with the thymomatous and non-thymomatous groups. The preoperative chest CT findings and current practices provide an explanation for this finding. If the preoperative chest CT reveals a suspected thymoma-liked nodular, then it is suggested that the patient undergoes surgery for the direct management of MG with thymoma. If the preoperative CT is negative, the patient should receive initial non-surgical (i.e. pharmacological) treatment. The increased age of patients in the thymolipoma group relative to patients in the non-thymomatous group may also explain the heightened duration of symptoms before surgery. Thymectomy has been documented to be beneficial to patients with MG, especially in younger patients and those with a short duration of symptoms before surgery [14, 18] . Neurologists responsible for the initial care of patients with MG may be less likely to initiate a surgical referral for patients who are CT-negative. Likewise, elderly patients may be less likely to be recommended for surgical treatment.
In contrast to thymomas, which sometimes show malignant behaviour, thymolipomas are believed to be benign tumours that do not infiltrate adjacent organs and do not metastasize [9] . Although a case involving malignant change in thymolipoma has been reported [19] , there were no instances of tumour recurrence in our series.
Pan et al. [20] noted that patients with thymolipoma without MG are younger than those with MG and that patients with thymolipomas and MG are often older than 50 years of age and have tumours weighing <100 g. The same phenomenon was observed in our cohort of patients and in another previously described series [9] . The mean age of patients in our study with MG and thymolipoma was 47.9 years and the mean weight of thymic tissue removed was 127.9 g. Although the weight of thymic tissue removed in our study is less than reported among cases of nonmyasthenic thymolipoma in the literature [4, 6] , the weight was still well above that for the non-thymomatous MG group (mean = 59.1 g). Compared with non-myasthenic thymolipoma patients, myasthenic thymolipoma patients were usually older, had smaller tumours, and were diagnosed after surgical intervention [3, 4] .
One of the proposed hypotheses regarding the pathogenesis of thymolipoma is fatty regression of a hyperplastic thymus or even development as part of aging [9, 21] . Interestingly, 10 of the 12 (83.3%) patients had received preoperative steroid treatment to control myasthenic symptoms, whereas with thymomatous MG, only 28 of the 104 (26.9%) patients were given preoperative steroids. Whether the use of steroids affects the aging process is unknown. Further studies are needed to clarify whether steroids hasten the effect of fatty degeneration in thymomas and stimulate transformation into thymolipomas. According to our observations, the diagnosis of thymolipoma should be kept in mind when treating older patients with MG and those who have a history of steroid treatment.
The association between thymolipoma and MG has been well documented [9, 10, 12, 20] ; however, there is limited information available concerning the remission rate of thymolipomatous MG compared with other types of MG. We believe that our study is the first to describe surgical results comparing thymolipomatous, thymomatous and non-thymomatous MG. Regarding the surgical outcomes after TET, the thymomatous group had a Figure 3 : Kaplan-Meier cumulative estimate of the CSR rates following extended thymectomy in MG. There were no between-group differences in the probability of a CSR event at any time point during the follow-up period as determined by the log-rank test (P = 0.261). Non-thymomatous (filled triangle); thymomatous (inverted triangle); thymolipomatous (filled circle).
significantly lower CSR compared with the thymolipomatous and non-thymomatous groups. Although the use of preoperative AchRAb titres, the immunological hallmark of MG, to predict the prognosis of individual patients has not been well documented [22] , the mean serum level of preoperative AchRAb was lowest in the nonthymomatous group, followed by the thymolipoma group, and then the thymomatous group. In addition, there were no between-group differences in the distribution of preoperative myasthenic severity. This may explain the relatively similar clinical outcomes between groups after extended thymectomy. Furthermore, postoperative improvement in the severity of myasthenia suggested that TET may be a feasible treatment modality for this group of patients. Note that, we have previously compared the use of RtVATET and TET in the treatment of MG and found both approaches to be equally effective [14, 16] .
This study has several limitations that warrant acknowledgment. First, the data analysed in this study were gathered only from a single institution. A greater number of patients and data from multiple centres should be collected in future analysis. Secondly, the small number of patients in the myasthenia thymolipomas group (relative to the other groups) may have affected the Kaplan-Meier estimates of CSR, i.e. the analysis to determine these estimates may have been somewhat underpowered. Therefore, it would be unwise for us to draw any definitive conclusions regarding these particular findings. Thirdly, the data analysed in our study were collected over a long period, and as such may have encompassed changes in clinical practice, including surgical equipment used, postoperative care, treatment protocols, etc. Such changes may have affected a number of variables assessed, including resected thymic weights, patient profiles and indeed surgical outcomes. We must emphasize, however, that the focus of this study was to make between-group comparisons as detailed herein. We did not aim to make any time period comparisons, although we acknowledge that such comparisons are worthy of investigation. The final limitation is that this study involved a highly selected series, i.e. only patients who underwent surgical intervention were selected and included in the study.
CONCLUSIONS
In conclusion, the results of this study suggest that patients with myasthenia thymolipomatous have surgical outcomes (in terms of CSR) similar to those of patients with non-thymomatous MG and have a mean age at time of surgery similar to that of patients with thymomatous MG. Given the small number of patients with thymolipomatous MG, our findings should be interpreted with the appropriate degree of caution. However, as thymolipomatous MG is clearly a rare phenomenon, we believe that these findings are an important contribution to the literature.
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